Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 10;4(1):e10251. doi: 10.1002/jbm4.10251

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Changes in bone turnover markers with transdermal estrogen treatment. (A) C‐terminal collagen cross‐links (CTX), a marker of bone resorption, decreased significantly after 3 and 6 months of treatment with transdermal estradiol (repeated measures analysis, p = 0.028). (B,C) Levels of N‐terminal propeptide of type 1 procollagen (P1NP) (B) and osteocalcin (C), both markers of bone formation, did not change significantly with transdermal estradiol treatment (repeated measures analysis for P1NP, p = 0.457 and repeated measures analysis for osteocalcin, p = 0.313). (D) Sclerostin decreased significantly after 3 months of treatment with transdermal estradiol, but levels increased and were similar to baseline levels after 6 months of treatment. The overall pattern of change was not statistically significant with repeated measures analysis (p = 0.150). *p = 0.003 compared with baseline levels; **p = 0.005 compared with baseline; ***p = 0.011 compared with baseline (paired sample t test). Plotted values are Mean ± SEM.